|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:administeredBy
|
oral medication
|
|
gptkbp:ATCCode
|
none (as of 2023)
|
|
gptkbp:CASNumber
|
944396-07-0
|
|
gptkbp:category
|
experimental cancer drug
|
|
gptkbp:clinicalTrialPhase
|
Phase III (as of 2023)
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:hasInChIKey
|
QZJXODVZJZQXQJ-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C18H21N5O2S
|
|
gptkbp:hasSMILES
|
CC1=CC(=NC2=C1N=CN=C2N3CCOCC3)C(=O)NC4=NC=CS4
|
|
gptkbp:hasUNII
|
6Z5B6HVF6O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
buparlisib
|
|
gptkbp:intendedUse
|
anticancer agent
|
|
gptkbp:investigatedBy
|
gptkb:cancer
solid tumors
|
|
gptkbp:IUPACName
|
2-(4-morpholin-4-ylpyrimidin-2-ylamino)-4-methylthieno[3,2-d]pyrimidine-6-carboxamide
|
|
gptkbp:mechanismOfAction
|
PI3K inhibitor
|
|
gptkbp:molecularWeight
|
371.46 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1800255
25016713
25216706
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
gptkb:BKM120
|
|
gptkbp:target
|
gptkb:phosphoinositide_3-kinase_(PI3K)
|
|
gptkbp:bfsParent
|
gptkb:PIK3CA
|
|
gptkbp:bfsLayer
|
5
|